HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program

Affiliation auteurs!!!! Error affiliation !!!!
TitreHORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program
Type de publicationJournal Article
Year of Publication2021
AuteursGrob J.J, Aubin F., Benmahammed-Bellagha L., Brunet-Possenti F., Dereure O., Dutriaux C., Duval-Modeste A-B., Grange F., Jarvis C., Kramkimel N., Leccia M-T., Machet L., Meyer N., Mortier L., Neidhardt E-M., Robert C., Scherrer E., Spampinato A., Verdoni L., Saiag P.
JournalANNALS OF ONCOLOGY
Volume32
PaginationS895
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.08.1465